Vantage logo

Pressure on Abbvie's pipeline grows

Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.

Vantage logo

Eidos chases Pfizer in amyloidosis

Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.